{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:31:09Z","timestamp":1784633469852,"version":"3.55.0"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Human Nutrition Diet"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chimeric antigen receptor T (CAR\u2010T) cell therapy is a novel therapy demonstrating durable remissions in patients with refractory or relapsing non\u2010Hodgkin's B\u2010cell lymphoma. Maintaining a patient's nutritional status has been demonstrated to improve outcomes in cancer treatment. However, no studies have investigated how CAR\u2010T therapy affects nutritional status, nor compared its impact with other cancer treatments for this patient group. The primary aim of the present study was to investigate the effect of CAR\u2010T therapy on the prevalence of nutrition impact symptoms (NIS) and nutritional status within 30 days post\u2010treatment of patients with lymphoma compared to a conditioning regimen for autologous haematopoetic stem cell transplant (carmustine\/<jats:italic>B<\/jats:italic>CNU, <jats:italic>Et<\/jats:italic>oposide, cytarabine\/<jats:italic>A<\/jats:italic>ra\u2010C, <jats:italic>M<\/jats:italic>elphalan [BEAM] auto\u2010haematopoetic stem cell transplant [HSCT]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical notes of patients with lymphoma who underwent either CAR\u2010T therapy or BEAM auto\u2010HSCT between 2018 and 2021 were reviewed. Data extracted included body weight measurements and NIS, including decreased appetite, nausea, vomiting, diarrhoea, constipation, mucositis, cytokine release syndrome (CRS) and neurotoxicity at baseline and 30\u2009\u00b1\u20097 days post\u2010treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 129 adults with lymphoma (<jats:italic>n<\/jats:italic>\u2009=\u200988 CAR\u2010T vs. <jats:italic>n<\/jats:italic>\u2009=\u200941 BEAM) were included. Nutritional status was assessed in both groups at baseline prior to treatment. Mean absolute weight change was significantly different between groups (3.05\u2009kg in CAR\u2010T, \u22125.9\u2009kg in BEAM, <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.001). This was also significant when weight loss was categorised into percentage weight loss (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). CAR\u2010T patients experienced a significantly lower prevalence of decreased appetite (52.3% vs. 97.6%) nausea (25% vs. 78%,) vomiting (10.2% vs. 53.7%), diarrhoea (43.2% vs. 96.7%) and mucositis (5.7% vs. 75.6%) combined across all levels of severity compared to BEAM chemotherapy (all <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.01). CRS and neurotoxicity, which are specific side effects of CAR\u2010T therapy, were moderately positively associated with weight loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Weight loss, percentage weight loss and NIS were significantly reduced in CAR\u2010T compared to BEAM treatment. However, patients who experienced neurotoxicity during treatment did have significant weight loss.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jhn.13210","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T08:43:47Z","timestamp":1690274627000},"page":"2099-2107","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The nutritional impact of CD19\u2010targeted CAR\u2010T therapy versus BEAM chemotherapy for adult patients with lymphoma"],"prefix":"10.1111","volume":"36","author":[{"given":"Katie","family":"Ahern","sequence":"first","affiliation":[{"name":"King's College Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pham","sequence":"additional","affiliation":[{"name":"King's College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-2833","authenticated-orcid":false,"given":"Robin","family":"Sanderson","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madson","family":"Correia De Farias","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Walsh","sequence":"additional","affiliation":[{"name":"King's College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Cancer Research UK. Non\u2010Hodgkin lymphoma incidence statistics. n.d. [cited 2021 Oct 30]. Available from:http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/non-hodgkin-lymphoma\/incidence"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-4-324"},{"key":"e_1_2_11_7_1","unstructured":"National Institute for Health and Care Excellence. Autologous anti\u2010CD19\u2010transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma. [Technology appraisal guidance TA677].2021[cited 2022 May 29]. Available from:https:\/\/www.nice.org.uk\/guidance\/ta677"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0582-9"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2017.06.017"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04952-5"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2473-z"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.7762\/cnr.2012.1.1.3"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13298"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000596"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06639-2"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/014860718000400503"},{"issue":"1","key":"e_1_2_11_20_1","first-page":"181","article-title":"The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: physicians poster session (P001\u2010P706)","volume":"55","author":"Ahern K","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_21_1","unstructured":"CucchiaroB SleeA DaviesNA WeekesCE. Presence of malnutrition and cachexia in adult CD\u201019 CAR T cell therapy patients and its association with patient outcomes. Poster session presented at theEBMT CAR\u2010T Meeting virtual.2022 February."},{"issue":"1","key":"e_1_2_11_22_1","first-page":"35","article-title":"Subjective global assessment of nutritional status: further validation","volume":"7","author":"Hirsch S","year":"1991","journal-title":"Nutrition"},{"key":"e_1_2_11_23_1","unstructured":"World Health Organization. Physical status: the use and interpretation of anthropometry [online].1995[cited 2021 Nov 11]. Available from:https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37003\/WHO_TRS_854.pdf?sequence=1&isAllowed=y"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.010"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2021.151159"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.10.015"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00132-3"},{"key":"e_1_2_11_29_1","unstructured":"National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B\u2010cell acute lymphoblastic leukaemia in people aged up to 25 years. [Technology appraisal guidance TA554] [online].2018[cited 2022 May 22]. Available from:https:\/\/www.nice.org.uk\/guidance\/ta554"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0476-3"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(05)80001-3"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.1894"},{"key":"e_1_2_11_33_1","first-page":"346","volume-title":"Bone Marrow Transplant","author":"Montoro\u2010Lorite M","year":"2021"},{"key":"e_1_2_11_34_1","unstructured":"RussellCA EliaM. Nutrition screening survey in the UK and Republic of Ireland in 2011. A report by the Malnutrition Advisory Group of the British Association for Parenteral and Enteral Nutrition (BAPEN)[online].2012[cited 2021 Nov 10]. Available from:http:\/\/www.bapen.org.uk\/pdfs\/nsw\/nsw-2011-report.pdf"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.105"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8340"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"}],"container-title":["Journal of Human Nutrition and Dietetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jhn.13210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T06:09:49Z","timestamp":1695276589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jhn.13210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/jhn.13210"],"URL":"https:\/\/doi.org\/10.1111\/jhn.13210","archive":["Portico"],"relation":{},"ISSN":["0952-3871","1365-277X"],"issn-type":[{"value":"0952-3871","type":"print"},{"value":"1365-277X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"2023-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}